According to the updated Next Day Disclosure Return dated 22 October 2025, Ascletis Pharma Inc. (01672) repurchased 100,000 shares on the Hong Kong Stock Exchange. The purchase represented 0.0101% of the issued shares excluding treasury shares and was executed at prices ranging from HKD 9.22 to HKD 9.34, with a total consideration of HKD 926,520. Following this transaction, the number of treasury shares increased from 6,184,210 to 6,284,210, while the total issued share capital remained at 998,958,530 shares.

Additional filings indicate multiple earlier repurchases for cancellation are still pending formal cancellation. The issuer’s share repurchase mandate, granted on 22 May 2025, covers up to 96,284,628 shares, with 660,000 shares repurchased under that mandate to date. A 30-day moratorium on new share issuance or the sale or transfer of treasury shares remains in effect until 21 November 2025.